Abzu er en kunstig intelligens (KI) virksomhed, der bygger forklarbar og gennemsigtig AI. Investeringen fra Innobooster People bruges til at videreudvikle virksomhedens forskning i algoritmiske metoder målrettet tidsserier. Ydermere bruges investeringen til at forskning og udvikling i forbedring af gennemsigtige og forklarbare KI-modeller. KI er fremtidens vækstdriver og kommende regulering peger i den retning som Abzu forsker i, og vil bidrage til en markant konkurrencefordel.

Ud fra erfaringerne fra det maritime marked ønsker vi at udvikle rundstråleantenner til det landbaserede område, hvor kravene til frekvenser og sendestyrker adskiller sig fra det maritime område. Vi har derfor behov for at udvikle nye antennetyper for at kunne gå ind på dette marked.

Acceleration of financial calculations will enable fast investment portfolio analysis for risk analysis and pricing of financial instruments by exploiting modern commodity many-core architectures for high-performance software implementations. The project will deliver fast parallel proto-types that demonstrates the potential for acceleration without compromising precision requirements and is benchmarked via direct integration in SimCorp Dimension.

Dette industrielle ph.d.-projekt bygger på et samarbejde mellem Rambøll, DTU og CBS med det formål at udvikle et open source, system dynamics modelling værktøj, der understøtter cirkulær forretningsmodelinnovation for SDG'erne i byggebranchen. Værktøjet vil vurdere cirkularitetsydelsen af aktuelle forretningsmodeller i byggebranchen, simulere og hjælpe med implementeringen af cirkulær forretningsmodelinnovation og vurdere og styre SDG-impacts af nyudviklede cirkulære forretningsmodeller.

Pipe | bio is a cloud based bioinformatics platform enabling pharmaceutical companies to develop life saving biological drugs - faster.

Evaxion develops vaccines against bacterial pathogens by discovering protective proteins using an in-house AI platform called EDEN. These proteins are cumbersome to design and develop for clinical testing, with significant preclinical development costs. We aim to greatly accelerate this process by generating improved structural models of the identified proteins using novel methodologies within deep learning and probabilistic programming, thus allowing the generation of clinically ready designs.

Lugtgener fra bilens ventilationsanlæg pga. akkumulering af bakterier og svamp er et velkendt problem, som kan have konsekvenser for sundhed og indeklima. ACD ApS har udviklet en innovativ løsning, ACD-Plugin, som er et lille UVC LED-lys i form af et plugin, tilpasset snævre og sværttilgængelige ventilationssystemer, som det der findes i biler. Den desinficerende effekt af UVC forstærkes af en antibakteriel TiO2-behandling, som med påvist effekt udraderer akkumulerede patogene.

DynElectro's patented operation method allows dynamic operation of large SOEC stacks with reduced degradation. DynElectro will mature the operation method to drive down the cost of PtX products.

Investeringen skal bruges til at udvikle et headset til high end gaming segmentet og fastholde flere af vores afgørende udviklingsmedarbejdere. Dette involvere udvikling af custom elektronik til ANC og bluetooth, samt algoritmer og materialer til det endelige produkt. Dette vil supplere vores eksisterende produkt til E-sport turneringer og styrke vores forretningspotentiale betydeligt.

ACOUPLAST aims to reach a 900M€/year market opportunity with the development of a polymer acoustofluidic chip for high-performing, fast and cost-effective plasma separation, to enable healthcare and veterinary Point-of-Care (PoC) diagnostics. Targeting life science companies, we will deliver AcouPlast chip modules for integration in single-use test cartridges. The solution is a recent research breakthrough by DTU Physics, experimentally validated by ACS, resulting in a patent application.

Akromegali er en sjælden sygdom forårsaget af øget niveauer af væksthormon, hvilket ofte er forårsaget af en godartet tumor i hypofysen. Flere studier peger på, at GIP receptoren (GIPR) kan forårsage de øgede væksthormonniveauer i en del af patienterne med akromegali. Vi er i den unikke situation, at vi har en GIPR antagonist, som kan bruges i mennesker. Med den vil vi klarlægge GIPRs involvering i akromegali og validere om GIPR antagonister kan bruges terapeutisk i denne patientgruppe.

Acter er en digital samarbejds og vidensdelingsplatform, der har til formål at skabe en ny digital infrastruktur der kan understøtte og accelerere handling på globale udfordringer, herunder FN’s 17 verdensmål.Hvad der gør platformen unik er Acters arkitektur kombineret med dets funktionaliteter, der er centreret omkring fire kerne moduler: Geo Mapping der skaber et overblik over økosystemet i realtid, en vidensbank til deling af afprøvede løsninger, samt samarbejds-og-rapporteringsværktøjer.

We aim at developing a novel an innovative treatment opportunity for schizophrenia. Schizophrenia encompasses three different disease domains recognized as positive, negative and cognitive symptoms. Current medication is inadequate against negative and cognitive symptoms. By pursuing a novel target that has demonstrated promising preclinical result we aim at developing a new treatment paradigm for untreated symptoms in schizophrenia thereby covering a high unmet need.

Obesity, diabetes, and cardiometabolic diseases are global crises threatening to cripple healthcare infrastructures. These metabolic disorders are driven by caloric excess and elevated blood glucose and lipid levels. We believe that increasing energy expenditure to burn off excess glucose and lipids holds the potential to counteract metabolic disorder. Attempts to exploit energy expenditure in humans have shown impressive efficacy but failed due to adverse side effects. One promising alternative approach is to activate thermogenic adipose, a type of fat tissue that can increase energy expenditure due to its unique evolutionary design to consume significant amounts of glucose and lipid from the blood to fuel calorie-burning. Yet targeting thermogenic adipose activity has proven difficult to date. However, we recently identified a novel G-protein coupled receptor, GPR3, which stimulates energy expenditure in human and mouse thermogenic adipocytes and lowers bodyweight and fully reverses diabetes in obese mouse models. Acting as a potent thermogenic adipose activator, GPR3 small molecule agonism would address a pressing, unmet need in the metabolic disorder market by promoting both weight loss and improve glucose and lipid metabolism. Moreover, given the lack of calorie-burning activators approved, GPR3 agonists hold the potential to be both first- and best-in-class therapeutics with an advantageous safety profile. Finally, the upside of an energy expenditure target is the combined efficacy against obesity, cardiovascular disease, and fatty liver/NASH. In the InnoExplorer project, we will generate proprietary small molecule GPR3 activators to obtain in vitro and in vivo efficacy and secure IP. These goals will allow us to form a new Danish spin-out company and secure a pharmaceutical collaboration or build an international syndicate for series A financing to accelerate the development of GPR3 small molecule agonists as a next generation therapeutic.